Jun 26, 2023 · An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss seen yet...

5 days ago · Eli Lilly and Company (NYSE: LLY) has announced that it will release late-stage data on its next-generation weight loss drug, retatrutide, in 2025, earlier than initially expected.

Jun 23, 2023 · Eli Lilly’s experimental pill for weight loss helped people lose an average of 15% of their body weight after 36 weeks on the highest dose in a midstage trial, rivaling what’s seen with...

Jan 26, 2025 · Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as effective as bariatric surgery.

Jan 13, 2025 · Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg.

Aug 27, 2024 · The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates...

Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks told Bloomberg News on Monday that data on the drug,...

INDIANAPOLIS, April 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.

Nov 9, 2023 · A new weight loss drug has been approved that promises to be the most effective medication yet. How is Zepbound, the weekly injectable drug that’s expected to be available shortly after ...

Jun 26, 2023 · New data from Eli Lilly show two of its anticipated weight-loss drugs— tirzepatide (Mounjaro) and orforglipron—were effective in recent studies.